Skip to main content
Autobound logo
Amgen10-Q: Capacity constraint

Amgen's new drugs UPLIZNA (+90%) and IMDELLTRA (>100%) see explosive volume growth

Read at SEC EDGAR

What happened

Rapid, volume-driven growth in newer drugs like UPLIZNA and IMDELLTRA is a key strategic success but creates potential operational challenges. This surge in demand could strain manufacturing, supply chain, and commercial support systems, creating a need for scalable solutions.

Source

SEC EDGARAug 4, 2026

Quarterly report (Form 10-Q)

Amgen 10-Q

Filing excerpt

The increases in global UPLIZNA sales for the three and six months ended June 30, 2026 were primarily driven by volume growth.

sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htmRead the full source

Other signals in this filing (7)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Capacity constraint

What this signalsFilings often name leadership changes, deals and spending plans.

Fiscal year end
06/30
Filed
Aug 4, 2026

More from Amgen

Company page →

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$335M (Total UPLIZNA sales for the three months ended June 30, 2026)
Percent
90% (Total UPLIZNA sales change YoY for the three months ended June 30)

Details

CIK
318154
Accession number
0000318154-26-000126
Timeframe
Current quarter
Filing year
2026
Fiscal year
0
Why it matters
Scaling solutions needed
Signal category
Operations

Topics and mentions

Regions named

  • United States
  • ROW

Extraction

Confidence
Medium
Relevance
80%
Sentiment
Neutral
Detected
Aug 11, 2026
signal_type
sec-10q
signal_subtype
capacityConstraint

Use this data

Get every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/56e13899-2854-4daf-9872-76b3dea02500 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "56e13899-2854-4daf-9872-76b3dea02500",
  "signal_type": "sec-10q",
  "signal_subtype": "capacityConstraint",
  "detected_at": "2026-08-11T08:09:12.392+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Rapid, volume-driven growth in newer drugs like UPLIZNA and IMDELLTRA is a key strategic success but creates potential operational challenges. This surge in demand could strain manufacturing, supply chain, and commercial support systems, creating a need for scalable solutions.",
    "metrics": {
      "pct": 0.9,
      "timeframe": "current_quarter",
      "pct_context": "Total UPLIZNA sales change YoY for the three months ended June 30",
      "dollar_context": "Total UPLIZNA sales for the three months ended June 30, 2026",
      "dollar_millions": 335
    },
    "summary": "Amgen's new drugs UPLIZNA (+90%) and IMDELLTRA (>100%) see explosive volume growth",
    "excerpts": "The increases in global UPLIZNA sales for the three and six months ended June 30, 2026 were primarily driven by volume growth.",
    "relevance": 0.8,
    "sentiment": "neutral",
    "confidence": "medium",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm",
    "filing_date": "2026-08-04",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "06/30",
    "sales_relevance": "Scaling solutions needed",
    "signal_category": "operations",
    "regions_mentioned": [
      "United States",
      "ROW"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.